ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Decreased quantitative transport mapping velocity in the middle cerebral artery-supplied temporal lobe in Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Female vulnerability to microvascular transport dysfunction emerges early across the Alzheimer's disease continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Increased MRI-derived parenchymal cerebral spinal fluid mapping in untreated obstructive sleep apnea patients.Neurobiology of disease · 2026Article
- Decreased quantitative transport mapping velocity in the middle cerebral artery-supplied temporal lobe in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionReduced blood perfusion has been observed in patients with Alzheimer's disease (AD), but the patterns of blood perfusion changes during AD progression remain insufficiently explored.
methodsQuantitative transport mapping (QTM) is a novel biophysical modeling-based method for quantifying blood perfusion velocity. In this study, we examined regional changes in perfusion velocity throughout AD progression by combining QTM velocity measurements with Granger causality analysis using cross-sectional data, as a secondary and exploratory analysis following our previous QTM work, aiming to offer a comprehensive view of the QTM velocity patterns based on the arterial territories.
resultsReduced QTM velocity was observed in the middle cerebral artery (MCA)-supplied regions for patients with mild cognitive impairment. The MCA-supplied temporal lobe is a driving region of QTM velocity changes in other brain regions. DISCUSSION: The temporal lobe supplied by the MCA is the earliest brain region to exhibit changes in QTM velocity, indicating its potential as an early biomarker for AD diagnosis. HIGHLIGHTS: Quantitative transport mapping (QTM) velocity was significantly reduced in the middle cerebral artery (MCA)-supplied regions among patients with mild cognitive impairment, compared to cognitively normal individuals. The temporal lobe supplied by the MCA is a driving region of QTM velocity changes in other brain regions. The temporal lobe supplied by the MCA has great potential as an early biomarker for AD diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.